1. Targeting of the Mitochondrial TET1 Protein by Pyrrolo[3,2- b ]pyrrole Chelators.
- Author
-
Antonyová V, Tatar A, Brogyányi T, Kejík Z, Kaplánek R, Vellieux F, Abramenko N, Sinica A, Hajduch J, Novotný P, Masters BS, Martásek P, and Jakubek M
- Subjects
- DNA, Hydrazones chemistry, Iron, Iron Chelating Agents, Mitochondrial Proteins, Molecular Docking Simulation, Dioxygenases metabolism, Pyrroles chemistry, Pyrroles pharmacology
- Abstract
Targeting of epigenetic mechanisms, such as the hydroxymethylation of DNA, has been intensively studied, with respect to the treatment of many serious pathologies, including oncological disorders. Recent studies demonstrated that promising therapeutic strategies could potentially be based on the inhibition of the TET1 protein (ten-eleven translocation methylcytosine dioxygenase 1) by specific iron chelators. Therefore, in the present work, we prepared a series of pyrrolopyrrole derivatives with hydrazide ( 1 ) or hydrazone ( 2 - 6 ) iron-binding groups. As a result, we determined that the basic pyrrolo[3,2- b ]pyrrole derivative 1 was a strong inhibitor of the TET1 protein (IC
50 = 1.33 μM), supported by microscale thermophoresis and molecular docking. Pyrrolo[3,2- b ]pyrroles 2 - 6 , bearing substituted 2-hydroxybenzylidene moieties, displayed no significant inhibitory activity. In addition, in vitro studies demonstrated that derivative 1 exhibits potent anticancer activity and an exclusive mitochondrial localization, confirmed by Pearson's correlation coefficient of 0.92., Competing Interests: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.- Published
- 2022
- Full Text
- View/download PDF